What You Should Know:
- Biostate AI, an innovator at the intersection of artificial intelligence and RNA sequencing raises $12M in Series A funding spearheaded by Accel, with participation from Gaingels, Mana Ventures, InfoEdge Ventures, and existing investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures. This brings the company's total funding to over $20M.
- The newly acquired funds will be pivotal in advancing Biostate AI’s mission to unlock affordable and
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Cycle Time is the New Currency of Drug Development
For years, the life sciences industry has been trying to address the same R&D challenges: rising costs, patient recruitment and retention, and difficulty maximizing ROI. Drug development is expensive, and failure rates remain high. Studies estimate the total cost to develop a new drug is between $300 million and nearly $4.5 billion. Meanwhile, clinical trial cycle times continue to lengthen – significantly impacting overall drug development timelines. Clinical trials are increasingly
Read More
Closing the Affordability Gap: How Automation is Advancing Biosimilar Adoption
Millions of Americans are currently facing a difficult choice: either pay for expensive biologic medications or ration doses to afford basic needs. Cost-related nonadherence (CRN) is where patients either skip or delay their medication due to cost concerns, a challenge that is widespread throughout the U.S. The financial burden is even greater for those managing multiple chronic conditions, where prescription costs can quickly add up to unmanageable amounts.
Despite the financial strain,
Read More
PhaseV Closes $50M to Advance AI Clinical Development
What You Should Know:
- PhaseV, a company at the forefront of applying artificial intelligence (AI) and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by Accel and Insight Partners, with participation from existing investors Viola Ventures, EXOR, and LionBird. This round brings PhaseV's total funding to date to $65M.
- The new capital is earmarked to fuel PhaseV’s mission to support pharmaceutical companies, biotech firms, and contract
Read More
QuantHealth Unveils Its Large Real-World Drug Model in AWS Marketplace
What You Should Know:
QuantHealth has launched LRDM v1.0, the world’s first clinical trial foundation model that simulates patient outcomes using data from over 100 million individuals and billions of clinical datapoints.This technology marks a pivotal shift by applying large-scale AI modeling to clinical trial design—where 90% of drug candidates fail—offering the potential to cut waste, reduce timelines, and improve success rates
QuantHealth Unveils First-Ever Clinical Trial
Read More
SHINE Technologies to Acquire Lantheus’ SPECT Imaging Business
What You Should Know:
- SHINE Technologies, a nuclear fusion company with an expanding platform of medical isotope products, today announced it has entered into a definitive agreement to acquire the SPECT (Single-Photon Emission Computed Tomography) business from Lantheus, a leading radiopharmaceutical-focused company.
- The strategic acquisition includes the portion of Lantheus' North Billerica, Massachusetts campus dedicated to the manufacturing of its SPECT products.
SHINE's
Read More
Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton
What You Should Know:
- Robotics startup Wandercraft has begun clinical trials for its new Personal Exoskeleton.
- Founded by Nicolas Simon, whose siblings face mobility challenges from Charcot-Marie-Tooth disease, Wandercraft aims to help individuals with spinal cord injuries, stroke, and other severe neuromuscular disorders stand and walk again using advanced robotics and artificial intelligence.
From Rehabilitation Tool to Personal Mobility
Wandercraft is already known
Read More
Verily Receives $14.7M Grant from Michael J. Fox Foundation to Create Rich Molecular Dataset for Parkinson’s Research
What You Should Know:
- Verily, an Alphabet company focused on health data platforms and AI, today announced it has received a significant $14.7M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
- The funding will support the generation of a comprehensive molecular dataset aimed at accelerating research into Parkinson’s disease.
Building on the Personalized Parkinson’s Project
The new initiative will leverage and significantly expand upon data
Read More
Basil Systems Secures $11.5M to Expand AI-Powered Intelligence Platform for Life Sciences
What You Should Know:
- Basil Systems, a provider of an AI-powered product lifecycle intelligence platform tailored for the life sciences industry, announced it has raised a total of $11.5M in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital.
- The infusion of capital is earmarked for significant expansion efforts, including enhancing its enterprise BasilIntel SaaS platform, deepening product capabilities, and accelerating the adoption of
Read More
Immunai & Parker Institute to Build Largest Single-Cell Immune Profiling Patient Database
What You Should Know:
- Immunai, a leading AI biotech company specializing in mapping the human immune system and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, announced today that they will build the world’s largest single-cell dataset from patients treated with standard-of-care (SoC) immunotherapy.
- Under the collaboration with PICI,
Read More
